Company news

Bluenergies Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BluEnergies announces advisory agreements

September 14, 2026

BluEnergies announces closing of non-brokered private placement of units for gross proceeds of C$20.7 million

July 23, 2026

BluEnergies announces upsize of non-brokered private placement of units for gross proceeds of up to C$20,700,000

July 21, 2026

BluEnergies announces non-brokered private placement is fully subscribed

July 9, 2026

Bluenergies announces non-brokered private placement of units for gross proceeds of up to C$10 million

July 9, 2026

Bluenergies and totalenergies progress operations, Harper Basin, offshore liberia

July 6, 2026

BluEnergies provides details of investor relations engagements

June 26, 2026

BluEnergies announces DTC eligibility, engagement of market maker and initiation of research coverage

April 27, 2026

BluEnergies announces financial advisory agreements with haywood securities inc. and canaccord genuity corp.

April 16, 2026

BluEnergies announces trading on OTCQX best market under the trading symbol "BLUGF"

March 30, 2026

BluEnergies secures top bid in gulf of america lease sale, engages independent Houston firm for reserve evaluation

March 19, 2026

BluEnergies announces engagement of Curzio Research, Inc. and appointment of Doug Allen, Senior Manager of Investor Relations

March 16, 2026

BluEnergies announces completion of warrant acceleration

March 12, 2026

BluEnergies announces warrant expiry acceleration

February 10, 2026

BluEnergies announces shares for services and option grant

January 16, 2026

Totalenergies partners with BluEnergies in its Harper Basin fan play, offshore liberia

January 15, 2026

BluEnergies announces CEO transition

May 8, 2025

BluEnergies Ltd. announces commencement of trading on the TSX venture exchange

April 14, 2025

BluEnrgies Ltd. (Formerly Acme Gold Company Limited) Announces Closing of Reverse Takeover Transaction

April 9, 2025

Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health

June 28, 2023

S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index and S&P/TSX 60 Index

September 2, 2022

BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences

April 4, 2019

BELLUS Health Announces Clearance of U.S. IND for BLU-5937 Phase 2 Study in Chronic Cough Patients

April 3, 2019

BELLUS Health Presents 2018 Highlights and 2019 Corporate Plan

February 21, 2019

BELLUS Health Updates BLU-5937 Top-Line Phase 1 Results Timeline to November 2018

November 14, 2018

BELLUS Health Announces Issuance of New U.S. Patent Claiming P2X3 Selectivity as a Means of Minimizing Taste Effects for its Lead Chronic Cough Drug Candidate BLU-5937

October 31, 2018

BELLUS Health Announces Appointment of Clinical Advisory Board

September 25, 2018

BELLUS Health to Present at Baird 2018 Global Healthcare Conference

August 30, 2018

BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2018

August 8, 2018

BELLUS Health Announces Patent Protection Secured in All Major Pharmaceutical Markets for Lead Drug Candidate BLU-5937

July 19, 2018

BELLUS Health Initiates Phase 1 Clinical Study for its Chronic Cough Drug Candidate, BLU-5937

July 9, 2018

BELLUS Health Presents BLU-5937 Preclinical Data and Updated Phase 1 Timeline at 2018 International Cough Symposium

June 27, 2018

BELLUS Health to Present at the 2018 International Cough Symposium

June 20, 2018

BELLUS Health Reports Financial and Operating Results for the First Quarter Ended March 31, 2018

May 15, 2018

BELLUS Health Responds to Recent Share Price Appreciation and Increased Trading Activity

April 30, 2018

BELLUS Health to Present at Bloom Burton & Co. Healthcare Investor Conference

April 26, 2018

BELLUS Health Reports Financial and Operating Results for the Year Ended December 31, 2017

February 21, 2018

BELLUS Health Receives Milestone Payment from Taro Pharmaceuticals

January 9, 2018

BELLUS Health to Present at Biotech Showcase(TM) 2018 Conference

January 4, 2018

BELLUS Health Closes $20M Common Share Financing

December 12, 2017

BELLUS Health Announces Pricing of up to $20M Equity Offering

December 5, 2017

BELLUS Health Announces Overnight Marketed Equity Offering

December 4, 2017

BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2017

November 8, 2017

BELLUS Health Appoints Dr. Clarissa Desjardins to its Board of Directors

September 27, 2017

BELLUS Health Chronic Cough Webcast Taking Place Today

September 20, 2017

BELLUS Health's Blu-5937 Significantly Reduces Cough Without Taste Disturbance in Two Preclinical Models

September 18, 2017

BELLUS Health to host webcast on chronic cough and treatment approach on September 20, 2017

September 6, 2017

BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2017

August 9, 2017

Daily Coverage on Healthcare Stocks: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics

July 12, 2017

BELLUS Health announces closing of the sale of its equity interest in FB Health for total consideration up to CA$2.5M

July 3, 2017

Older news releases →

Decks